top of page
The Professional Network for Healthcare Experts
FDA approves Lyrfigtu for previously treated FGFR2-altered cholangiocarcinoma
The FDA has approved Lyrfigtu for adults with previously treated FGFR2-altered cholangiocarcinoma, adding a new targeted therapy for this molecularly defined group of bile duct cancers.
nuaxia
Sep 241 min read
FDA grants Fast Track designation to Phanes’ spevatamig for first-line metastatic pancreatic cancer
The designation broadens regulatory support for the CLDN18.2 × CD47 bispecific antibody as Phanes advances its chemotherapy combination through Phase II development in metastatic pancreatic ductal adenocarcinoma.
nuaxia
Aug 192 min read
bottom of page